Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
Expensive and softening.
Trading above fair value while the fundamentals weaken — little to like right now.
The five checks
2 good · 3 warning
- WarningOvervaluedFair value ~$32 vs $73 — trading 56% above what the math supports.
- WarningPrice assumes a big accelerationYou'd need ~16%/yr free-cash-flow growth to justify today's price; it has done 6.8%/yr lately.
- WarningRevenue shrinkingDown 0.4% last year — cheap may mean broken.
- GoodCash flow compoundingFree cash flow up ~6.8%/yr — the engine is growing.
- GoodFortress balance sheetNet cash positive (+$0B) — little solvency risk.
Price against fair value
What today's price assumes
Hold the price fixed and work backwards: how fast would free cash flow have to grow for $73 to make sense?
Price assumes a big acceleration.
How fair value is calculated
No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.
- Free cash flow, FY26Operating cash flow less capital spending, from the annual report$0B
- Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$2B
- Everything after year tenGrowing 2.5% a year, counted the same way+ $3B
- The business, in today's money$5B
- Add net cashCash and securities less borrowings and finance leases+ $0B
- Divide by the shares on file÷ 0.157B
Fair value per share$32
If our assumptions are wrong
Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $24 to $44 range comes from.
| 3% growth | 5% growth | 7% growth | |
|---|---|---|---|
| 8% discount | $32 | $38 | $44 |
| 9% discount | $27 | $32 | $37 |
| 10% discount | $24 | $28 | $32 |
The blue cell is the published method. Every cell sits below today’s price.
Free cash flow, ten years
$ billions · Form 10-K
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
How this was built. Every figure is computed from Bio-Techne Corporation's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY26 annual report and change only when a new one is filed. Price of $72.80 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.
Read Bio-Techne another way
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →